Eli Lilly said its next-generation obesity drug, retatrutide, showed weight-loss results comparable to bariatric surgery in a late-stage clinical trial.
These results suggest a potential shift in how severe obesity is treated, offering a pharmacological alternative to invasive surgical procedures for patients with high body mass index (BMI).
The Phase 3 trial lasted 80 weeks [5]. According to the data, participants receiving a 12 mg dose experienced an average weight loss of 28.3% [1]. Within that same high-dose group, 45.3% of participants lost more than 30% of their total body weight [2].
Lower doses also demonstrated significant efficacy over the 80-week period. The nine mg dose group saw an average weight loss of 25.9% [3], while the four mg dose group experienced an average loss of 19% [4].
Retatrutide is designed to be more powerful than existing obesity medications. By targeting multiple receptors, the drug aims to provide a more aggressive treatment option for those struggling with severe obesity who may not be candidates for surgery, or who prefer a non-surgical route.
The pharmaceutical company based in the U.S. is positioning the drug as a successor to its previous treatments, aiming for higher efficacy in weight reduction and metabolic improvement.
“retatrutide showed weight-loss results comparable to bariatric surgery”
The emergence of retatrutide indicates a trend toward 'triple-agonist' therapies that mimic multiple hormones to suppress appetite and increase energy expenditure. If these results hold, the drug could reduce the clinical reliance on bariatric surgery, potentially lowering surgical complications and costs for healthcare systems while expanding treatment access for patients with severe obesity.
